The University of Chicago Header Logo

Connection

Ravi Salgia to Carcinoma, Non-Small-Cell Lung

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Carcinoma, Non-Small-Cell Lung.
Ravi Salgia
Connection Strength
22.871
Carcinoma, Non-Small-Cell Lung
  1. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
    View in: PubMed
    Score: 0.500
  2. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Cold Spring Harb Mol Case Stud. 2023 04; 9(2).
    View in: PubMed
    Score: 0.485
  3. Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 02 10; 41(5):1129-1131.
    View in: PubMed
    Score: 0.468
  4. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol. 2022 11; 86(Pt 2):233-246.
    View in: PubMed
    Score: 0.458
  5. The next targets for small cell lung cancer. Clin Adv Hematol Oncol. 2022 01; 20(1):35-36.
    View in: PubMed
    Score: 0.442
  6. Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules. 2021 12 21; 12(1).
    View in: PubMed
    Score: 0.441
  7. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
    View in: PubMed
    Score: 0.421
  8. Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. JCO Oncol Pract. 2021 08; 17(8):e1120-e1130.
    View in: PubMed
    Score: 0.418
  9. Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clin Lung Cancer. 2021 09; 22(5):e703-e707.
    View in: PubMed
    Score: 0.414
  10. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
    View in: PubMed
    Score: 0.414
  11. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6).
    View in: PubMed
    Score: 0.411
  12. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report. Medicine (Baltimore). 2020 Nov 13; 99(46):e22323.
    View in: PubMed
    Score: 0.409
  13. Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? JCO Oncol Pract. 2021 01; 17(1):52-53.
    View in: PubMed
    Score: 0.399
  14. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncol Pract. 2021 02; 17(2):e257-e265.
    View in: PubMed
    Score: 0.399
  15. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer. 2020 08; 146:174-181.
    View in: PubMed
    Score: 0.395
  16. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
    View in: PubMed
    Score: 0.392
  17. Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. Int J Oncol. 2020 07; 57(1):80-86.
    View in: PubMed
    Score: 0.391
  18. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344.
    View in: PubMed
    Score: 0.365
  19. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res. 2019; 178:3-43.
    View in: PubMed
    Score: 0.359
  20. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. J Oncol Pract. 2018 09; 14(9):569-571.
    View in: PubMed
    Score: 0.348
  21. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
    View in: PubMed
    Score: 0.338
  22. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
    View in: PubMed
    Score: 0.327
  23. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
    View in: PubMed
    Score: 0.318
  24. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
    View in: PubMed
    Score: 0.308
  25. KRAS in Non-Small-Cell Lung Cancer-Reply. JAMA Oncol. 2016 10 01; 2(10):1373-1374.
    View in: PubMed
    Score: 0.307
  26. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. BMC Cancer. 2016 08 02; 16:568.
    View in: PubMed
    Score: 0.304
  27. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016 Jun 01; 2(6):805-12.
    View in: PubMed
    Score: 0.300
  28. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70.
    View in: PubMed
    Score: 0.300
  29. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016 07; 16(7):737-49.
    View in: PubMed
    Score: 0.300
  30. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
    View in: PubMed
    Score: 0.297
  31. Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol. 2016; 12(8):1045-58.
    View in: PubMed
    Score: 0.294
  32. Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. Am J Clin Oncol. 2015 Oct; 38(5):442-7.
    View in: PubMed
    Score: 0.287
  33. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. J Clin Neurosci. 2015 Dec; 22(12):1978-9.
    View in: PubMed
    Score: 0.282
  34. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf. 2015 Mar; 14(3):485-93.
    View in: PubMed
    Score: 0.274
  35. Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncol. 2015; 11(3):489-500.
    View in: PubMed
    Score: 0.272
  36. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med. 2014 Jun; 3(3):681-92.
    View in: PubMed
    Score: 0.259
  37. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
    View in: PubMed
    Score: 0.257
  38. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117.
    View in: PubMed
    Score: 0.254
  39. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncol. 2014 Jan; 3(1):61-75.
    View in: PubMed
    Score: 0.254
  40. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
    View in: PubMed
    Score: 0.253
  41. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014 Feb 01; 343(1):14-23.
    View in: PubMed
    Score: 0.249
  42. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
    View in: PubMed
    Score: 0.239
  43. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer. Am J Respir Crit Care Med. 2012 Nov 15; 186(10):940-1.
    View in: PubMed
    Score: 0.235
  44. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
    View in: PubMed
    Score: 0.232
  45. Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51.
    View in: PubMed
    Score: 0.227
  46. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011 Dec; 11(12):1655-62.
    View in: PubMed
    Score: 0.220
  47. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1810-1.
    View in: PubMed
    Score: 0.218
  48. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011 Sep 01; 117(17):3889-99.
    View in: PubMed
    Score: 0.208
  49. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94.
    View in: PubMed
    Score: 0.208
  50. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.206
  51. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther. 2010 Mar 15; 9(6):409-16.
    View in: PubMed
    Score: 0.195
  52. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.
    View in: PubMed
    Score: 0.176
  53. Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007 Nov; 7(6):633-42.
    View in: PubMed
    Score: 0.166
  54. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34.
    View in: PubMed
    Score: 0.159
  55. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94.
    View in: PubMed
    Score: 0.158
  56. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88.
    View in: PubMed
    Score: 0.137
  57. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2023 11; 24(7):651-659.
    View in: PubMed
    Score: 0.124
  58. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30.
    View in: PubMed
    Score: 0.119
  59. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
    View in: PubMed
    Score: 0.119
  60. Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clin Lung Cancer. 2023 05; 24(3):244-251.
    View in: PubMed
    Score: 0.119
  61. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
    View in: PubMed
    Score: 0.118
  62. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003; 8(1):69-75.
    View in: PubMed
    Score: 0.118
  63. Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk. J Cancer Res Clin Oncol. 2023 Jul; 149(8):5231-5240.
    View in: PubMed
    Score: 0.117
  64. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002 Nov 01; 62(21):6304-11.
    View in: PubMed
    Score: 0.117
  65. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiother Oncol. 2022 08; 173:10-18.
    View in: PubMed
    Score: 0.114
  66. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54.
    View in: PubMed
    Score: 0.111
  67. Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients. J Thorac Oncol. 2022 02; 17(2):194-196.
    View in: PubMed
    Score: 0.111
  68. ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready? JCO Precis Oncol. 2021 11; 5:767-770.
    View in: PubMed
    Score: 0.109
  69. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2021 08; 30(8):1498-1505.
    View in: PubMed
    Score: 0.106
  70. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med. 2021 04; 10(8):2660-2667.
    View in: PubMed
    Score: 0.105
  71. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001 Mar-Apr; 21(2B):1241-6.
    View in: PubMed
    Score: 0.104
  72. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Clin Lung Cancer. 2021 09; 22(5):e678-e683.
    View in: PubMed
    Score: 0.103
  73. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2021 01; 22(1):e84-e97.
    View in: PubMed
    Score: 0.101
  74. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. J Biol Chem. 2020 09 18; 295(38):13393-13406.
    View in: PubMed
    Score: 0.100
  75. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Commun Signal. 2019 12 16; 17(1):167.
    View in: PubMed
    Score: 0.096
  76. The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer. Bioinformatics. 2019 08 15; 35(16):2738-2748.
    View in: PubMed
    Score: 0.094
  77. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer. 2019 07; 133:136-143.
    View in: PubMed
    Score: 0.092
  78. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncol. 2019 Aug; 58(8):1095-1101.
    View in: PubMed
    Score: 0.091
  79. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77.
    View in: PubMed
    Score: 0.090
  80. Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma. Lung Cancer. 1998 Nov; 22(2):149-52.
    View in: PubMed
    Score: 0.089
  81. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Semin Oncol. 2018 08; 45(4):210-219.
    View in: PubMed
    Score: 0.087
  82. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
    View in: PubMed
    Score: 0.085
  83. Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar; 16(3):1207-17.
    View in: PubMed
    Score: 0.085
  84. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185.
    View in: PubMed
    Score: 0.084
  85. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189.
    View in: PubMed
    Score: 0.079
  86. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460).
    View in: PubMed
    Score: 0.078
  87. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
    View in: PubMed
    Score: 0.077
  88. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
    View in: PubMed
    Score: 0.076
  89. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9.
    View in: PubMed
    Score: 0.073
  90. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.
    View in: PubMed
    Score: 0.070
  91. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015 Aug; 26(8):1741-8.
    View in: PubMed
    Score: 0.070
  92. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015 Jul; 89(1):43-9.
    View in: PubMed
    Score: 0.069
  93. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
    View in: PubMed
    Score: 0.068
  94. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71.
    View in: PubMed
    Score: 0.067
  95. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64.
    View in: PubMed
    Score: 0.066
  96. Increased µ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014 Jul; 113 Suppl 1:i103-8.
    View in: PubMed
    Score: 0.065
  97. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577.
    View in: PubMed
    Score: 0.064
  98. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.064
  99. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. Int J Med Sci. 2013; 10(8):988-94.
    View in: PubMed
    Score: 0.061
  100. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41.
    View in: PubMed
    Score: 0.061
  101. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.060
  102. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
    View in: PubMed
    Score: 0.059
  103. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9.
    View in: PubMed
    Score: 0.058
  104. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
    View in: PubMed
    Score: 0.057
  105. Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67.
    View in: PubMed
    Score: 0.056
  106. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.056
  107. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.055
  108. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38.
    View in: PubMed
    Score: 0.054
  109. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12.
    View in: PubMed
    Score: 0.054
  110. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
    View in: PubMed
    Score: 0.054
  111. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67.
    View in: PubMed
    Score: 0.053
  112. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
    View in: PubMed
    Score: 0.053
  113. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011 May; 6(5):942-6.
    View in: PubMed
    Score: 0.053
  114. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol. 2011 Apr; 6(4):786-9.
    View in: PubMed
    Score: 0.052
  115. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7.
    View in: PubMed
    Score: 0.052
  116. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011 Mar; 112(3):558-67.
    View in: PubMed
    Score: 0.051
  117. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6.
    View in: PubMed
    Score: 0.051
  118. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
    View in: PubMed
    Score: 0.051
  119. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30.
    View in: PubMed
    Score: 0.048
  120. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med. 2008 Dec; 132(12):1882-8.
    View in: PubMed
    Score: 0.045
  121. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.044
  122. MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79.
    View in: PubMed
    Score: 0.044
  123. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
    View in: PubMed
    Score: 0.040
  124. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
    View in: PubMed
    Score: 0.039
  125. A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther. 2006 Dec; 5(12):1600-7.
    View in: PubMed
    Score: 0.039
  126. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol. 2006 Jan; 3(1):50-7; quiz 1 p following 57.
    View in: PubMed
    Score: 0.036
  127. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005 Mar 15; 11(6):2312-9.
    View in: PubMed
    Score: 0.034
  128. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. Ann Thorac Surg. 2004 Aug; 78(2):450-7.
    View in: PubMed
    Score: 0.033
  129. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
    View in: PubMed
    Score: 0.028
  130. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022 01; 11(1):21-27.
    View in: PubMed
    Score: 0.027
  131. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
    View in: PubMed
    Score: 0.025
  132. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
    View in: PubMed
    Score: 0.019
  133. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
    View in: PubMed
    Score: 0.017
  134. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.